Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

被引：0
|
作者：
Xiaoying Gu
Su Zhang
Xuejiao Yang
Tao Guan
Zhenyu Hou
Manqing Cao
Huikai Li
Ti Zhang
机构：
[1] Tianjin Medical University Cancer Institute and Hospital,Department of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[2] National Clinical Research Center for Cancer,Department of Gynecologic Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[3] Tianjin Medical University Cancer Institute and Hospital,Present Address: Department of Anesthesiology
[4] National Clinical Research Center for Cancer,Department of Breast Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[5] The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Present Address: Department of Hepatic Surgery
[6] Tianjin Medical University Cancer Institute and Hospital,undefined
[7] National Clinical Research Center for Cancer,undefined
[8] Fudan University Shanghai Cancer Center,undefined
[9] Shanghai Medical College,undefined
[10] Fudan University,undefined
来源：
BMC Gastroenterology | / 22卷
关键词：
Apatinib; Anti-angiogenesis therapy; Adverse Events; Hepatocellular Carcinoma; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
    Zheng, Zhuangzhuang
    Liu, Zijing
    Zhang, Haifeng
    Guo, Xiao
    Jia, Xiaojing
    Wang, Jianfeng
    Meng, Lingbin
    Xin, Ying
    Jiang, Xin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Laboratory monitoring to reduce adverse drug-related events: a mixed methods study
    Harrison, Teresa N.
    Reynolds, Kristi
    Hahn, Erin E.
    Munoz-Plaza, Corrine E.
    Yi, David K.
    Fischer, Heidi
    Luong, Tiffany Q.
    Sim, John J.
    Brettler, Jeffrey
    Handler, Joel
    Mittman, Brian S.
    Singh, Hardeep
    Kanter, Michael H.
    Danforth, Kim N.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (01): : 16 - 25
  • [33] Can Online Data Lead To the Earlier Detection of Drug-Related Adverse Events?
    Duh, Mei S.
    Cremieux, Pierre
    van Audenrode, Marc
    Vekeman, Francis
    Karner, Paul
    Zhang, Haimin
    Greenberg, Paul
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 468 - 469
  • [34] Efficacy of camrelizumab and apatinib combination therapy versus apatinib only in treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Swed, Sarya
    Motawea, Karam R.
    AbdelQadir, Yossef Hassan
    Gamal, Mohamed
    El-Sakka, Amro A.
    Kandil, Omneya A.
    Abdelazeem, Basel
    Abdelaziz, Muhammad
    Wahsh, Engy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16147 - E16147
  • [35] What we may we learn.: Drug-related adverse events?
    Aranaz-Andrés, JM
    MEDICINA CLINICA, 2006, 126 (03): : 97 - 98
  • [36] Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib
    Sun, Fang
    Liu, Kai-Cai
    Ul Ain, Qurat
    Lu, Dong
    Zhou, Chun-Ze
    Xiao, Jing-Kun
    Zhang, Xing-Ming
    Zhang, Zheng-Feng
    Cheng, Deng-Lei
    He, Yu-Sheng
    Lv, Wei-Fu
    BMC GASTROENTEROLOGY, 2024, 24 (01) : 129
  • [37] Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
    Kobayashi, Kazuo
    Suzuki, Kenichi
    Hiraide, Makoto
    Aoyama, Takeshi
    Yokokawa, Takashi
    Shikibu, Sari
    Hashimoto, Koki
    Iikura, Yusuke
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    ONCOLOGY, 2020, 98 (04) : 237 - 242
  • [38] Searching for Drug-Related Adverse Events in PubMed/MEDLINE Using the MeSH Term “Drug Toxicity”
    M. O. Garcia
    F. A. Guzman
    Drug Safety, 2008, 31 : 885 - 885
  • [39] Searching for Drug-Related Adverse Events in PubMed/MEDLINE Using the MeSH Term "Drug Toxicity"
    Garcia, M. O.
    Guzman, F. A.
    DRUG SAFETY, 2008, 31 (10) : 889 - 889
  • [40] Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma
    Lu, Lianghe
    Xing, Kaili
    Wei, Wei
    Ling, Yihong
    Li, Peng
    Li, Shaohua
    Wang, Yan
    Xie, Dan
    Guo, Rongping
    Cai, Muyan
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 959 - 966
12345